Forma Therapeutics Holdings Inc (OQ:FMTX)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 500 Arsenal Street, Suite 100
Tel: N/A
Website: N/A
Key People
Business Overview
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for patients with rare hematologic diseases and cancers. Its pipeline consists of seven product candidates, two of which it is pursuing as core product candidates for development: FT-4202 for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Its other product candidate includes FT-2102 (Olutasidenib), FT-8225, FT-4101, CC-95775 and BI-1701963. FT-4202 is an oral, once-daily, potentially disease-modifying therapy. FT-4202 is a potent activator of pyruvate kinase-R (PKR), designed to improve RBC metabolism, function and survival, and potentially resulting in both increased hemoglobin levels and reduced VOCs. FT-7051, is a potent and selective inhibitor of CREB-binding protein/E1A binding protein p300 (CBP/p300).
Financial Overview
For the three months ended 31 March 2020, Forma Therapeutics Holdings Inc revenues decreased from $72M to $0K. Net income applicable to common stockholders increased 44% to $7.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from $0.15 to $0.21.
Employees: 77 as of Apr 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $1,681M as of Mar 31, 2020
Annual revenue (TTM): $28.55M as of Mar 31, 2020
EBITDA (TTM): -$103.40M as of Mar 31, 2020
Net annual income (TTM): -$51.33M as of Mar 31, 2020
Free cash flow (TTM): -$120.84M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 41,508,773 as of Jun 19, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization